Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Share Post:

Strengthen Your Customer Connections

Understanding the world prescribers are living in allows for more meaningful customer interactions. MAP Training Programs build your knowledge on marketplace trends impacting providers and the pharmaceutical industry today. 

Begin learning today

Achieve Company Goals

Bring teams up-to-speed on the latest market access trends impacting their unique selling environment.

View custom training solutions

Keep Your Finger on The Pulse

Subscribe to the Marketplace Blog to stay up-to-date on the latest trends impacting pharma

*required





    Privacy Guaranteed — We will never share your info

    Marketplace Blog

    Trends in the Marketplace

    Fractures in The 340B Program

    The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps

    The Impact of Medicare Price Negotiations

    The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law’s anticipated impact.

    Interpreting the Evidence

    Some of the best training occurs when the audience can be directly engaged in a live workshop. Learning objectives from our pre-work modules can be reinforced using activity-based adult learning principles during these sessions.

    The Value Perspective Model uses these live workshops to apply knowledge about the market, learned through pre-work training, and about the customer, discovered with a research workbook, to begin defining strategies. Matrix team collaboration can be maximized through these workshops.

    We can design workshops using our Subject Matter Experts or yours, and facilitate the delivery to ensure a smooth and professional training event.

    For more information Contact Us

    Manufacturers Restricting 340B Sales to Contract Pharmacies

    • Abbvie
    • Amgen
    • AstraZeneca
    • Boehringer Ingelheim
    • Eli Lilly
    • Merck
    • Novartis
    • Novo Nordisk
    • Sanofi
    • UCB
    • United Therapeutics
    • and more…